Colchicine for cardiovascular secondary prevention: evidence from recent trials and meta-analyses.
PURPOSE OF REVIEW Residual inflammatory risk remains an important driver of recurrent vascular events despite contemporary lipid-lowering and antithrombotic therapies. Low-dose colchicine is the first widely available anti-inflammatory therapy to be incorporated into contemporary guidelines for secondary prevention in...